Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of CYH33 in PIK3CA-related overgrowth spectrum (PROS) and PIK3CA-related vascular malformations (PRVM)
CTR20231410Phase 2Active
- Sponsor
- Haihe
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of risovalisib mesylate in PIK3CA-related overgrowth spectrum (PROS), PIK3CA-related vascular malformation (PVM), sponsored by Haihe. Started May 2023; status: active.
02
Drugs
risovalisib mesylate
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)PIK3CA-related vascular malformation (PVM)
Beyond the preview
Go deeper on CTR20231410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231410.